![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
JM Wu, DE Nitecki, S Biancalana and RI Feldman
Department of Protein Biochemistry and Biophysics, Berlex Biosciences, Richmond, California 94804-0099, USA.
Human bombesin receptor subtype 3 (BRS-3) was cloned based on its homology to the human gastrin-releasing peptide (GRP) receptor and neuromedin B (NMB) receptor. Some bombesin-like peptides were shown to activate BRS-3 expressed in Xenopus laevis oocytes, but only at relatively high concentrations, which suggests that BRS-3 is an orphan receptor. To study the pharmacology of BRS-3 in the context of a mammalian cell, we used BR2 cells, which are Balb/3T3 fibroblasts transfected with BRS-3 cDNA. A number of bombesin-like peptides found in mammals and amphibians stimulated calcium mobilization in BR2 cells but exhibited no effect on nontransfected parental Balb/3T3 cells. Of these peptides, NMB (EC50 approximately 1-10 microM) was the most active for stimulation of calcium mobilization. Testing of a series of NMB analogs truncated at the amino terminus and carboxyl terminus indicated that the minimal size of NMB required for retention of full activity was Ac-NMB(3-10). Systematically replacing each residue with alanine, or changing its chirality, demonstrated that the carboxyl- terminal residues His8, Phe9, and Met10 of NMB are important for optimal activity. We also tested whether a number of bombesin (BN) analogs that are potent pure or partial antagonists of the GRP receptor can activate BRS-3 in BR2 cells. One such analog, D-Phe6-BN(6-13) propyl amide, activated BRS-3-mediated calcium mobilization with an EC50 level of 84 nM. Through additional synthesis, we generated a significantly more potent analog, D-Phe6-Phe13-BN(6-13) propyl amide, which displayed an EC50 level of 5 nM for activation of BRS-3. Taken together, our data show that the core portions of bombesin-like peptides required for activation of BRS-3 are similar to those necessary for activation of the GRP and NMB receptors and thus provide pharmacological evidence that BRS-3 is in the BN receptor family. Furthermore, we have identified an agonist of BRS-3, namely D-Phe6- Phe13-BN(6-13) propyl amide, which is roughly 1000-fold more potent than BRS-3 agonists described previously.
This article has been cited by other articles:
|
|
 |
|
  R. T. Jensen, J. F. Battey, E. R. Spindel, and R. V. Benya International Union of Pharmacology. LXVIII. Mammalian Bombesin Receptors: Nomenclature, Distribution, Pharmacology, Signaling, and Functions in Normal and Disease States Pharmacol. Rev., March 1, 2008; 60(1): 1 - 42. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. Mantey, D. H. Coy, L. K. Entsuah, and R. T. Jensen Development of Bombesin Analogs with Conformationally Restricted Amino Acid Substitutions with Enhanced Selectivity for the Orphan Receptor Human Bombesin Receptor Subtype 3 J. Pharmacol. Exp. Ther., September 1, 2004; 310(3): 1161 - 1170. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. W. Moody, S. A. Mantey, T. K. Pradhan, M. Schumann, T. Nakagawa, A. Martinez, J. Fuselier, D. H. Coy, and R. T. Jensen Development of High Affinity Camptothecin-Bombesin Conjugates That Have Targeted Cytotoxicity for Bombesin Receptor-containing Tumor Cells J. Biol. Chem., May 28, 2004; 279(22): 23580 - 23589. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I L P Beales, C Beglinger, F S Lehmann, and P Hildebrand Regulation of gastric function by gastrin releasing peptide Gut, June 1, 2002; 50(6): 897 - 898. [Full Text] [PDF]
|
|
|
|
 |
|
 P. E. Squires, R. M. Meloche, and A. M. J. Buchan Bombesin-evoked gastrin release and calcium signaling in human antral G cells in culture Am J Physiol Gastrointest Liver Physiol, January 1, 1999; 276(1): G227 - G237. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. R. Ryan, H. C. Weber, S. A. Mantey, W. Hou, M. E. Hilburger, T. K. Pradhan, D. H. Coy, and R. T. Jensen Pharmacology and Intracellular Signaling Mechanisms of the Native Human Orphan Receptor BRS-3 in Lung Cancer Cells J. Pharmacol. Exp. Ther., October 1, 1998; 287(1): 366 - 380. [Abstract] [Full Text]
|
|
|
|
|
|
R. R. Ryan, H. C. Weber, W. Hou, E. Sainz, S. A. Mantey, J. F. Battey, D. H. Coy, and R. T. Jensen Ability of Various Bombesin Receptor Agonists and Antagonists to Alter Intracellular Signaling of the Human Orphan Receptor BRS-3 J. Biol. Chem., May 29, 1998; 273(22): 13613 - 13624. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. A. Mantey, H. C. Weber, E. Sainz, M. Akeson, R. R. Ryan, T. K. Pradhan, R. P. Searles, E. R. Spindel, J. F. Battey, D. H. Coy, et al. Discovery of a High Affinity Radioligand for the Human Orphan Receptor, Bombesin Receptor Subtype 3, Which Demonstrates That It Has a Unique Pharmacology Compared with Other Mammalian Bombesin Receptors J. Biol. Chem., October 10, 1997; 272(41): 26062 - 26071. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. A. Mantey, D. H. Coy, T. K. Pradhan, H. Igarashi, I. M. Rizo, L. Shen, W. Hou, S. J. Hocart, and R. T. Jensen Rational Design of a Peptide Agonist That Interacts Selectively with the Orphan Receptor, Bombesin Receptor Subtype 3 J. Biol. Chem., March 16, 2001; 276(12): 9219 - 9229. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
